Sustained major molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood stem cell transplantation in a patient with imatinib-resistant myeloblastic-phase chronic myeloid leukaemia

MeSH terms

• Benzamides
• Dasatinib
• Drug Resistance, Neoplasm
• Humans
• Imatinib Mesylate
• Leukemia, Myeloid, Chronic-Phase / drug therapy*
• Leukemia, Myeloid, Chronic-Phase / therapy
• Middle Aged
• Peripheral Blood Stem Cell Transplantation / methods*
• Piperazines / pharmacology*
• Pyrimidines / pharmacology*
• Pyrimidines / therapeutic use*
• Remission Induction
• Thiazoles / therapeutic use*
• Transplantation, Autologous